nuc-1031
Small moleculeexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Oct 1, 2012 (NCT01621854)
Timeline
Indications
Mechanism of action
- DNADISRUPTING AGENT
DNA disrupting agent
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- nuc-1031
- nuc-1031
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04163900 | Phase 3 | Nov 30, 2019 | Nucana, University of Toronto |
| NCT03146663 | Phase 2 | Jun 1, 2017 | Nucana |
| NCT02303912 | Phase 1 | Nov 1, 2014 | University of London, University of Oxford |
| NCT01621854 | Phase 1 | Oct 1, 2012 | Nucana, University of London |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Nucana | For profit | 3 | 2 | 3 | 2012 |
| University of London | Academic/Hospital | 2 | 2 | 1 | 2012 |
| University of Oxford | Academic/Hospital | 1 | 0 | 1 | 2014 |
| University of Toronto | Academic/Hospital | 1 | 0 | 1 | 2019 |
4 organizations
Page 1 / 1